# Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

> **NCT03850769** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Borderline Resectable Pancreatic Cancer

## Interventions

- **DRUG:** nab-paclitaxel and S-1

## Key facts

- **NCT ID:** NCT03850769
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-01
- **Primary completion:** 2022-03
- **Final completion:** 2022-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03850769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03850769, "Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03850769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*